Somewhat Positive News Coverage Somewhat Unlikely to Impact Crispr Therapeutics (CRSP) Stock Price

Media coverage about Crispr Therapeutics (NASDAQ:CRSP) has been trending somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Crispr Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.7141437842985 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

CRSP has been the topic of a number of recent research reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $53.70 price objective (down from $67.00) on shares of Crispr Therapeutics in a research note on Friday, March 9th. BidaskClub upgraded shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. Finally, ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $53.53.

Crispr Therapeutics (CRSP) opened at $51.77 on Friday. Crispr Therapeutics has a one year low of $13.50 and a one year high of $61.24. The stock has a market cap of $2,732.59, a P/E ratio of -30.10 and a beta of 3.63.

In related news, insider Tyler Dylan-Hyde sold 15,000 shares of the stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $20.55, for a total transaction of $308,250.00. Following the completion of the sale, the insider now owns 115,204 shares of the company’s stock, valued at $2,367,442.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Aktiengesellschaft Bayer bought 527,472 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The shares were purchased at an average cost of $22.75 per share, with a total value of $11,999,988.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 283,850 shares of company stock worth $7,261,865. Insiders own 39.98% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3269737/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-crispr-therapeutics-crsp-stock-price.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

FCB Financial  Earns Daily News Impact Score of 0.12
FCB Financial Earns Daily News Impact Score of 0.12
Under Armour  Upgraded by Deutsche Bank to Hold
Under Armour Upgraded by Deutsche Bank to Hold
Verizon Communications  Rating Increased to Overweight at Barclays
Verizon Communications Rating Increased to Overweight at Barclays
Zacks Investment Research Upgrades WEC Energy Group  to Buy
Zacks Investment Research Upgrades WEC Energy Group to Buy
Watsco  PT Set at $185.00 by Stephens
Watsco PT Set at $185.00 by Stephens
Ashford  Stock Rating Lowered by Zacks Investment Research
Ashford Stock Rating Lowered by Zacks Investment Research


© 2006-2018 Ticker Report. Google+.